Canada markets close in 4 hours 47 minutes

Resverlogix Corp. (RVX.TO)

Toronto - Toronto Real Time Price. Currency in CAD
Add to watchlist
0.05500.0000 (0.00%)
As of 09:35AM EDT. Market open.
Full screen
Previous Close0.0550
Bid0.0550 x 0
Ask0.0600 x 0
Day's Range0.0500 - 0.0550
52 Week Range0.0500 - 0.1700
Avg. Volume33,317
Market Cap15.098M
Beta (5Y Monthly)0.73
PE Ratio (TTM)N/A
EPS (TTM)-0.0800
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Resverlogix Announces Change to Its Board of Directors

    Calgary, Alberta--(Newsfile Corp. - February 21, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix" or the "Company") today announced that Shawn Lu has stepped down from the Board of Directors, effective today. "We would like to thank Shawn for his contributions and wish him all the best," said Donald McCaffrey, Resverlogix's President and CEO. About ResverlogixFounded in 2001, Resverlogix is a Calgary based late-stage biotechnology company, and a world leader in epigenetics, with the goal ...

  • Newsfile

    Resverlogix Announces Publication of its 40th Scientific Journal Article on Apabetalone's Potential Therapeutic Benefits

    Calgary, Alberta--(Newsfile Corp. - January 11, 2024) - Resverlogix Corp. (TSX: RVX) ("Resverlogix", "the Company") today announced publication of an article, entitled, "The BET inhibitor apabetalone decreases neuroendothelial proinflammatory activation in vitro and in a mouse model of systemic inflammation," by Dr. Sylwia Wasiak and colleagues, in Translational Neuroscience. This publication marks the 40th peer-reviewed scientific journal article published by Resverlogix researchers on apabetal

  • Baystreet

    Stocks in play: Resverlogix Corp.

    Today announced the publication of a peer-reviewed article, entitled "Apabetalone, a Clinical-stage, ...